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Vascular access is the lifeline of a hemodialysis patient. Currently arteriovenous ﬁstula and graft are considered the permanent
options for vascular access. Monitoring and surveillance of vascular access are an integral part of the care of hemodialysis patient.
Although diﬀerent techniques and methods are available for identifying access dysfunction, the scientiﬁc evidence for the optimal
methodology is lacking. A small number of randomized controlled trials have been performed evaluating diﬀerent surveillance
techniques. We performed a study of the recent literature published in the PUBMED, to review the scientiﬁc evidence on diﬀerent
methodologies currentlybeingusedforsurveillance andmonitoringandtheirimpactonthecareofthedialysis access. Thelimited
randomized studies especially involving ﬁstulae and small sample size of the published studies with conﬂicting results highlight
the need for a larger multicentered randomized study with hard clinical end points to evaluate the optimal surveillance strategy
for both ﬁstula and graft.
1.Introduction
Vascular access is the lifeline of a hemodialysis patient. The
evolution of vascular access has come a long way since the
days of Scribner Shunt [1]. Currently arteriovenous ﬁstula
(AVF) and arteriovenous graft (AVG) have been recognized
as the permanent accesses for a dialysis patient with tun-
neled cuﬀed catheter (TCC) being the bridge to obtain
a permanent access. Fistula First Breakthrough Initiative
with its eﬀorts to highlight the importance of autologous
arteriovenous ﬁstula and to educate the nephrologists,
vascular surgeons, and patients has yielded a progressive
improvement in the number of patients who are currently
using the ﬁstula for hemodialysis. In May 2011, the national
arteriovenousﬁstularatereached58.6%[2].Thoughwehave
increased the use of the autologous arteriovenous ﬁstula,
a number of complications such as thrombosis, infection,
stenosis, and access loss have plagued the care of these
accesses. Vascular access failure has economic as well as
adequacy of dialysis delivery implications. Measures taken
foroptimizationofvascularaccessconsumesabout8%ofthe
Medicare spending on end-stage renal disease (ESRD), yet
evidenceonhowtoevaluateandtreatthefactorswhichaﬀect
the vascular access function is at best suboptimal [3]. Mean-
while, vascular access problems like low blood ﬂow rates and
loss of patency are frequently noted in dialysis units. These
issues and other complications lead to extended treatment
times, underdialysis, and frequent hospitalizations [4].
The Dialysis Outcome Quality Initiative Guidelines
(DOQI) published by the National Kidney Foundation has
provided a list of techniques which could be applied for
monitoring and surveillance of vascular accesses [5]. Center
for Medicare and Medicaid Services (CMS) mandates that
both monitoring and surveillance be part of the dialysis
care being provided to the ESRD patients with an aim of
identifying and intervening at an early stage, with the intent
of controlling the spiraling costs of access care [6]. Though
various techniques are in use for this purpose, no clear
consensus has been reached regarding the most optimal
surveillance technique which identiﬁes a failing access of
all types. We performed a systematic literature review to
identify various surveillance techniques and its eﬀects on
access function outcomes.
2. Methods andResults
In order to understand the available surveillance techniques
and their eﬀects on vascular access outcomes, we performed
a PUBMED search through July 2011 of articles in English
language, limited to the last 20 years, and available as full2 International Journal of Nephrology
articles. The following MeSH terms used in the search
“hemodialysisvascularaccess”[AllFields]OR“hemodialysis
vascular access monitoring” [All Fields] OR “haemodialysis”
[All Fields] OR “renal dialysis” [MeSH Terms] OR “renal”
[All Fields] AND “dialysis” [All Fields] OR “renal dialysis”
[All Fields] OR “hemodialysis” [All Fields] AND “blood ves-
sels” [MeSH Terms] OR “blood” [All Fields] AND “vessels”
[All Fields] OR “blood vessels” [All Fields] OR “vascular”
[All Fields] AND access [All Fields] AND “epidemiology”
[Subheading] OR “epidemiology” [All Fields] OR “surveil-
lance” [All Fields] OR “epidemiology” [MeSH Terms] OR
“surveillance” [All Fields] OR transonic [All Fields] AND
access [All Fields] AND ﬂow [All Fields] OR diﬀerential [All
Fields] AND conductivity [All Fields] AND technique [All
Fields] OR clinical [All Fields] AND monitoring [All Fields]
AND“haemodialysis”[AllFields]OR“renaldialysis”[MeSH
Terms] OR “renal” [All Fields] AND “dialysis” [All Fields]
OR “renal dialysis” [All Fields] OR “hemodialysis” [All
Fields] AND access [All Fields]. This resulted in 4412 pub-
lications. We then identiﬁed, reviewed, and extracted those
studies which evaluated the various surveillance techniques,
either comparing diﬀerent surveillance modalities or were
randomized studies. We then focused on those studies in
which access outcome was the primary objective. We found
only 7 studies with randomization and 17 studies where a
cohort of patients was used. All studies were prospective
with access outcome as an end point. There were six studies
whichevaluatedonlytheautologousAVF,eightstudiesabout
AVG, and 10 studies where AVF and AVG were combined in
the primary analysis. The discussion below summarizes the
ﬁndings and conclusions from these studies.
3. Discussion
3.1. Monitoring and Surveillance Techniques. Monitoring
strategies include physical examination (inspection, palpa-
tion, and auscultation) of the vascular access to detect
physical signs that suggest the presence of physical pathology
[7]. It also includes review of routine laboratory studies
regularlyobtainedinthedialysisunit,dialysisadequacy(urea
reduction ratio or Kt/V), and diﬃculties in cannulation or
achieving hemostasis after needle withdrawal, documented
recirculation, and other clinical clues. Physical examination
oftheaccessbyanexperiencedindividualhashighsensitivity
and speciﬁcity [8–10]. Measurement of dynamic venous
pressure (DVP) during dialysis is currently considered as a
monitoring strategy rather than a surveillance tool. Most of
the modern dialysis machine measures the dynamic venous
pressure during treatment, but the utility of dynamic venous
pressure at ﬂows 150–200mL/min in detecting stenosis or
predicting access thrombosis is very limited [11]. DVP is
crucially dependent on the needle gauge and the length of
the metallic portion of the dialysis needle. In addition, the
length and the thickness of the needle shaft vary among
manufacturers. In most dialysis units revalidation of the
measurement procedures are usually not done with change
of needle type [11, 12].
Surveillance, on the other hand, mandates periodic eval-
uation of the Vascular Access by means of speciﬁcally de-
signed tests that may involve special instrumentation, for
which an abnormal test result suggests the presence of pa-
thology. Surveillance tests require additional time and eﬀort
from staﬀ and in some circumstances dedicated technicians
or nurses to yield consistent results. Access ﬂow meas-
urement [5, 13–15], duplex Doppler ultrasound [16–18],
and direct or derived static pressure [19, 20] are the
frequently used surveillance tools studied in the literature,
ﬂow measurement being the most widely used technique.
Access ﬂow is measured by inducing forced recirculation
where the arterial and venous blood lines are reversed.
A signal is engendered either by infusion of a substance
(saline, glucose), change in ultraﬁltration rate (change in
hematocrit), or addition of sodium (change in conductance)
in the venous return line [14]. Most ﬂow measurements
are done at blood pump ﬂows of 200–300mL/min to avoid
the increasing diﬀerence between actual blood ﬂow and the
blood pump ﬂow at higher prepump pressure. During the
interval of measurement, eﬀective dialysis is reduced.
Duplex ultrasound studies (DUSs) can provide an inde-
pendent accurate measure of blood pump blood ﬂow. DUS
measurement can be made in a few minutes producing
virtually no eﬀect on Kt/V, but routine use of it may be
limited by cost and operator skill. The delta hematocrit
method can reduce the eﬀective treatment time for up to 8–
10minutes,whereastheconductivity-basedmethodcantake
u pt o2 0m i n u t e so rm o r e[ 15, 21].
Static venous pressure is another well-established tech-
nique for detecting physiologically signiﬁcant stenosis in
AVG [19, 22] and is able to reduce graft thrombosis [22, 23].
Its usefulness in predicting thrombosis or access failure in
AVF is currently unknown. After initial description of the
technique by Besarab et al., measurement of the static intra-
access pressure (Pia) has evolved over time. Original method
required a pressure transducer between the venous return
tubing and the venous needle and connected to a pressure
monitor. As intra-access pressure is inﬂuenced by mean
arterial pressure (MAP), Pia is normalized to MAP as a ratio
Pia/MAP. Pia/MAP ratio of 0.5 has a sensitivity of 81% and
speciﬁcity of 80% in detecting a stenosis >50% by diameter
[24]. The same group evolved a computerized method using
the dynamic pressure readings taken during any dialysis
session and extracting from it the static pressure while
factoring out the contributions of chair heights, blood pump
ﬂow, and hematocrit [25]. The evolved method achieves the
same result in AVF and AVG [19].
The rationale for monitoring and surveillance should be
to improve longevity of the vascular access, reduce thrombo-
sis rate and the use of temporary catheters. Understanding
the pathophysiological eﬀect of the stenosis is important
in interpreting ﬁndings of monitoring and surveillance
tools. Access dysfunction occurs mostly due to underlying
stenosis.Stenosiseventuallyreducesaccessﬂowandaltersthe
pressure proﬁles and is nearly always a prerequisite for access
thrombosis [26, 27]. In reality access ﬂow and pressures vary
during and between dialysis sessions. Variation occurs due
to cannulation technique, changes in hemodynamic among
the dialysis sessions [28–30]. Therefore, a single measure-
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an evolving stenosis [28]; rather multiple repetitive measure-
ments are required [31–33]. The relationship between blood
ﬂow and intra-access pressure in a stenotic access depends
on the location of the lesions [34]. One single technique may
not be able to detect lesions at various locations that can
occur in an access. Frequently multiple lesions are common
in the territory of a vascular access, and the physiologic
eﬀect produced will depend on whether these are simple
lesion at the inﬂow or outﬂow of the access or mixed
(both inﬂow and outﬂow), their time of occurrence, and
the progression of the stenosis independently over time or
concurrently [31, 35]. In general an outﬂow stenosis causes
an increase in intra-access pressure and overtime decreases
access ﬂow [36]. Clinically it can be manifested as prolonged
postneedle withdrawal bleeding, aneurismal dilatation, and
development of recirculation. This is particularly more
evident in AVG than in AVF. In AVF some of the intra-access
pressure can be dissipated by the development of collaterals.
Determination of the rate of progression of the stenotic
lesions is crucial for timing of intervention and to prevent
unnecessary intervention. Angioplasty of the subclinical
stenosis does not improve access outcome rather could
promotestenosis[37].Therefore,sequentialmeasurementof
pressureorﬂoworbothisrequiredtoidentifyaccessesatrisk
which will need intervention. The eﬀect of inﬂow stenosis
diﬀers from outﬂow lesions. With inﬂow stenosis intra-
access pressure either remains stable or decreases and the
accessﬂow may decrease withoutany change in the prepump
pressure setting of the dialysis machine [36]. Surveillance
tools based on pressure monitoring may not be able to
detect such stenosis. But it can be detected by sequential ﬂow
measurement or physical examination [31, 32].
The study conducted by Tessitore et al. [34] indicates
that the best test to detect a given stenosis depends on its
location. Flow measurement is useful for identifying inﬂow
stenosis, whereas derived static venous pressure is a better
tool for outﬂow lesions. As mentioned before, an access can
have multiple lesions involving both inﬂow and outﬂow. It
is, therefore, imperative to implement a process rather than
a single method in detecting stenosis.
Vascular accesses are abandoned in large part due to irre-
versible thrombosis which in many times is preceded by one
or more episodes of reversible thrombosis. This is especially
true for AVG. In several observational studies, it was noted
thattheprimarypatencyofthegraftafterelectiveangioplasty
(70% to 85%) is superior to angioplasty after thrombectomy
(37% to 63%) [38]. This ﬁnding favors implementation of a
surveillance method to detect graft stenosis prior to throm-
bosis and preemptive angioplasty to improve graft survival.
In search of an optimal surveillance tool, many observational
studies have been conducted comparing diﬀerent surveil-
lance techniques and their ability to identify accesses at risk.
We should keep in mind that an abnormal surveillance
data should always be correlated with clinical ﬁndings
to determine the need for referral for intervention. At
present there is little quality assurance for the success of
intervention other than anatomical success. At most access
center, peri-procedural assessment of intra-access pressure
or ﬂow measurements are unavailable to be correlated
with prediction of secondary access patency. Several studies,
Tessitore et al. [39], Murray et al. [40], and Van der Linden et
al. [41], found that higher post intervention Qa was the only
variableassociatedwithimproved accesslongevity. Although
both DOQI guideline and CMS mandate implementation
of surveillance methods, they do not prefer one surveillance
technique over another due to lack of suﬃcient evidence in
the literature [5].
3.2. Observational Studies
3.2.1. Intervention before Thrombosis through Surveillance.
Four observational studies by May et al. [42], Wang et
al. [43], Paulson et al. [44], and McDougal and Agarwal
[45] tested the positive predictive value and sensitivity of
the access ﬂow in predicting graft thrombosis. In these
studies only 25% to 43% of the grafts with baseline ﬂow of
<500 to 700mL/min developed thrombosis over the next 3
months. Neyra et al. tested this hypothesis in a prospective
manner. Their study showed only 26% of the AVG with
a 25% decrease in access ﬂow thrombosed over the next
3 months [46]. The accuracy of the correlations may be
strongly inﬂuenced by the accuracy and timing of the access
ﬂow measurement. Flow measurements are time dependent
and vary during dialysis as well as within dialysis sessions.
The study conducted by Polkinghorne et al. [47]m e a s u r e d
blood ﬂow multiple times during the dialysis session for
3 consecutive sessions. They noted signiﬁcant reduction
in ﬂow and MAP throughout the dialysis treatment in a
progressive manner. Flow can decrease by 10–30.6% during
the last hour of dialysis. Similar results were found by
Huisman et al. [48] using duplex Doppler ultrasound and
Doppler ultrasound studies methods.
Besarab et al. [22] conducted a prospective observational
study to test the utility of static venous pressure to detect and
correct venous outlet stenosis prior to thrombosis. Observa-
tion period was quite long for 7.75 years, and a total of 832
patient-access years of risk was monitored. 65% to 80% of
theaccesseswereprosthetic graft.Theresultof thisstudy was
very promising; static venous pressure/systolic BP was found
to provide excellent criteria for angiographic referral and
intervention of >50% stenosis using angioplasty or surgical
revision. There was marked reduction of the thrombosis rate
(70%) and access replacement rate (79%) compared with
the historical baseline. Similar observational studies using
diﬀerent surveillance tools also showed promising results.
Speciﬁcally Sands et al. [49] showed a 6.5-fold reduction in
thrombosis rate from 1.25 to 0.19 events per patient year at
risk (duplex ultrasound imaging) and Mccarley et al. [50]
a 4.4-fold reduction from 0.71 to 0.16 (access ﬂow). Both
Hoeben et al. [51] and Glazer et al. [52]a c h i e v e da2 - f o l d
reduction in thrombosis events, from 0.32 to 0.17- (using
ﬂow methodology).
The utility of combining ﬂow monitoring and static
venous pressure was tested by another observational study
conducted by Smits et al. [11]; this study fails to show any
advantage of combining the 2 surveillance strategies. On
the contrary, recent observational study by Plantinga et al.
[53] on 363 prospectively followed incident dialysis patients4 International Journal of Nephrology
did not ﬁnd any advantage of using such surveillance. A
similar ﬁnding was also observed by Shahin et al. [54].
In the era of automation, Zasuwa et al. have described
a novel methodology using an automated noninvasive
surveillancealgorithmwhichincorporatesthevascularaccess
pressure ratios. They studied the thrombosis rates during
a baseline 6-month period to the subsequent 6-month
periods when the algorithm was applied. A vascular access
pressure ratio of >0.55 was considered signiﬁcant. No special
instruments or clinical staﬀ was required for this automated
process which generated a warning list of patients who had
abnormal results. After 18 months of implementation, the
thrombosis rate decreased from 0.29 to 0.13 events per
patient-access-year, an impressive 57% decrease [55].
3.3. Randomized Controlled Trials. Randomized controlled
trials are the gold standard for evidence in medicine. Inter-
ventional nephrology is a relatively new subspecialty. Very
few RCTs have been conducted involving the vascular access.
Twelve RCTs have been published; eight of them describing
outcomes in AVG and 4 in AVF. There are two additional
studies on reanalysis of the published data. Nine studies
compared surveillance and intervention versus usual clinical
monitoring and intervention in 1363 participants [49, 53,
56–62], including two studies which were prospective cohort
studies [53, 61]. Sample size of the individual trials ranged
from 51 to 189 with a mean of 151 and a mean duration
of 17 months (range of 6–28 months). The other ﬁve were
trials of patients with abnormal surveillance results who are
randomly allocated to intervention (either percutaneous or
surgical) or usual clinical monitoring. These 5 trials included
336 participants with a follow-up period of 12–15 months
[37, 63–66]. All of the studies have their own limitations
concerning sample size, population characteristics, method
of surveillance, poor reporting of allocation concealment,
blinding, vintage of the access in use, recruitment criteria,
and the method of intervention. See Table 1.
Sands et al. [49] studied 103 patients (68 AVF and 35
AVG) in a randomized controlled study to see whether
frequent monitoring on a monthly basis rather than 6
monthly evaluations minimize access thrombosis. They also
compared the eﬃcacy of the two surveillance techniques,
access ﬂow, and static venous pressure. The study popula-
tions were randomized into three groups: monthly measure-
ment of access ﬂow (Qa), monthly measurement of static
venous pressure (VPS), or no monthly monitoring (control
group). Color ﬂow Doppler ultrasound was performed in
all patients every 6 months. In the ﬂow group criteria for
referral were access ﬂow <800mL/min in AVG and <600mL
in AVF or a ≥25% decline in ﬂow. In the static pressure
monitoring group, static venous pressure ratios >0.5 were
referred for angiography and angioplasty of >50% stenosis.
Mean follow-up time was 197 days. Their study showed that
intervention based on monthly surveillance decreased access
thrombosis both in AVF and AVG (P<0.01) compared to no
monitoring. In this study, measurement of access ﬂow tends
to result in lower thrombosis rates than the static venous
pressure. This study has several limitations. In regards to
static venous pressure, they used the same intervention
criteria for ﬁstula and graft, as we know that ﬁstulae have
lower static venous pressure than AVG and remain patent at
a low ﬂow state [67]. Moreover, the criteria for intervention
were based upon changes in ﬂow rate (≥25% decline in
ﬂow rate) but not changes in static pressure readings over
time, which may limit the eﬃcacy of pressure monitoring.
Lastly accesses in the control group were older than those
in the monitoring group (851.7 days versus 542.8 days, P<
0.05). This study did not answer whether more frequent
monitoring is needed to see beneﬁcial results.
M o i s te ta l .[ 58] conducted a randomized controlled trial
that studied 112 prevalent patients with AV graft comparing
monthly Qa plus standard surveillance (dynamic venous
pressure and physical examination) to standard surveillance
alone. Patients were referred for intervention if ﬂow was
<650mL/min or 20% decrease in ﬂow in the treatment
group. This study showed no diﬀerence in time to graft
loss (P = 0.890). In multivariate analysis, only aspirin
therapy was associated with an 84% reduction in risk of graft
thrombosis (odds ratio 0.14; P = 0.002).
The randomized trial published by Ram et al. [62]i n
2002 followed 101 patients with AV grafts for up to 24
months. The study population was randomized in three
groups: control group, ﬂow (Qa), or stenosis groups. All
patients had monthly ﬂow measurement with ultrasound
dilutionandquarterlypercentstenosisbyduplexultrasound.
Criteria for referral and preemptive percutaneous trans-
luminal angioplasty (PTA) of >50% stenosis were clinical
monitoring for control group, ﬂow <600mL/min or clinical
criteria for ﬂow group, and stenosis >50% or clinical criteria
for stenosis group. Flow and stenosis groups had higher
preemptive PTA rate (0.34/patient year and 0.65/patient year
resp.)comparedtothecontrolgroup(0.22/patientyear).The
higher PTA rate in the intervention group failed to prolong
graft survival (62% in control, 60% in ﬂow, and 64% in
stenosis group, P = 0.89). There was reduced rate of graft
thrombosis seen in the stenosis group (47% in control, 53%
ﬂow, and 29% in stenosis group, P = 0.10), but it did not
reach statistical signiﬁcance which could have resulted from
t h es m a l ls a m p l es i z ei ne a c hg r o u p .
Malik et al. [56] conducted a multicenter randomized
prospective study to observe the eﬀect of surveillance by
classic Doppler ultrasound versus clinical monitoring on
patency of AVG. The sample size was 192, mean followup
392 ± 430 days. This study showed longer graft patency by
regular Doppler ultrasound screening by early detection of
access stenosis and intervention. But the intervention rate
was quite high, therefore increasing the cost of care. An
overall cost analysis was not performed.
In AVG studies, the surveillance programs have led
to increased detection of stenosis and higher angioplasty
rates. AVFs are known to have less frequent stenotic rates
which may raise the question if surveillance programs
lead to increased detection of the stenosis among ﬁstulae.
Polkinghorne et al. [59] reported a randomized, double-
blind prospective controlled study to evaluate if access ﬂow
surveillance of AVF results in increased detection of AVF
stenosis. Of a total of 137 patients, 68 patients were assigned
to access ﬂow measurements and 67 patients to the controlInternational Journal of Nephrology 5
Table 1: Randomized trials comparing surveillance and intervention versus usual clinical monitoring and intervention.
Name Total no.
of patients Control Study
patients Surveillance methods tested Primary outcome Result
Mayer et al., 1993 [57] 70 35 35 Ultrasound evaluation of stenosis Graft survival Positive
Sands et al., 1999 [49] 103 41 62 Access ﬂow, static venous pressure Access thrombosis Positive
Moist et al., 2003 [58] 112 53 59 Access ﬂow, dynamic venous
pressure Access thrombosis, loss Negative
Ram et al., 2003 [62] 101 34 67 Access ﬂow, stenosis Access thrombosis, survival Negative
Roca-Tey et al., 2004 [61]∗ 159 65 94 Access ﬂow Access thrombosis Positive
Malik et al., 2005 [56] 192 92 97 Ultrasound evaluation of stenosis Cumulative patency Positive
Plantinga et al., 2006 [53]∗ 363 185 178 Multiple Multiple outcomes Positive
Polkinghorne et al., 2006 [59] 137 67 68 Access ﬂow >50% stenosis Negative
Robbin et al., 2006 [60] 126 61 65 Ultrasound evaluation of stenosis Graft survival Negative
∗Prospective nonrandomized studies.
group. The primary end point was angiographically sig-
niﬁcant stenosis. Access ﬂow was measured by ultrasound
dilution technique (Transonic Inc, USA). The results showed
that patients in surveillance group were twice as likely to
be detected with an angiographically signiﬁcant stenosis
compared to the controls group (control hazard ratio (HR)
conﬁdence interval (CI) (2.27, 95% 0.85–5.98, P = 0.09).
There was a trend towards earlier detection of stenosis in
the surveillance group. When using access ﬂow alone, there
was a moderate prediction of (>50%) AVF stenosis (0.78,
95% CI 0.63–0.94, P<0.006). Surveillance does add to
earlier recognition of a dysfunctional ﬁstula although how
this will translate into hard clinical end points is yet to
be determined. This study also highlights that, although
there can be diﬃculty in performing blinded randomized
controlled trials in the care of the ﬁstula, it is not impossible.
Robbin et al. [60] studied 126 hemodialysis grafts in
prospective randomized clinical trials comparing ultrasound
surveillance and clinical monitoring in graft outcomes. 61
were randomized to receive routine clinical monitoring,
and 65 were randomized to receive duplex ultrasound
surveillance every four months in addition to routine clinical
monitoring. The mean followup was about 22 months
(21.9 months in ultrasound group and 22.9 months in
control group). The ultrasound group had more frequent
angioplasty (64% higher) than the control group without
any added beneﬁt in terms of graft thrombosis or surgical
intervention. The hazard ratio for graft survival in the
ultrasound group was 0.93 (95% CI 0.53 to 1.64). A
subgroup analysis restricted to patients with virgin grafts
revealednosigniﬁcantdiﬀerencewithrespecttotimetograft
failure (P = 0.32) or thrombosis-free survival (P = 0.72).
One of the major limitations of the study was surveillance
frequency which was done every four months; whether more
frequent surveillance would improve graft longevity is yet to
bedetermined.Alsothespontaneousvariationinﬂowwithin
theaccesswasnotassessed.Withoutsuch,manyaccessesmay
have been prematurely acted upon because of the presence
of a lesion which was not hemodynamically signiﬁcant.
Finally, the quality of monitoring which was used in both
groups may have been suﬃc i e n tt od e t e c tm o s ts t e n o s i s .A s
stated previously, physical examination of the access by an
experiencedindividualhashighsensitivityandspeciﬁcity[8–
10]. Unfortunately such high-skill level is missing in most
dialysis centers. See Table 2.
The ﬁrst randomized control trial that was conducted by
Lumsden et al. [37] in 1997 investigated the eﬀect of pro-
phylactic percutaneous transluminal angioplasty (PTA) to
prolong the patency of AVG in high-risk predominantly
inner-city African-American dialysis patients; almost a third
of the population were also diabetic. The grafts studied were
not all virgin; the majority had surgical or percutaneous
intervention prior to enrolment. The sample size was 64
in 2 dialysis units. Color ﬂow duplex ultrasound was used
to detect >50% stenosis, which was subsequently con-
ﬁrmed by angiography. Those who had >50% stenosis
were randomized to balloon angioplasty versus observation;
follow-up period was 12 months. There was no signiﬁcant
diﬀerence in patency in two groups at 6 months and 12
months. Although the demographically study populations
were matched, there were more prior interventions and
central stenosis in the intervention group than in control
group, which may inﬂuence the result. Subgroup analysis
of the 21 virgin grafts by the same group showed improved
long-term patency with surveillance [68].
In 1999, Martin et al. [64] conducted a subset analysis
of the above study. In the study population 21 patients had
virgin grafts that had never undergone surgery, PTA, or
thrombolysis. Among the virgin grafts, eight patients were
randomized to the treatment group and 13 to the control
g r o u p .T h ev i r g i ng r o u p sw e r ew e l lm a t c h e da st oa g e ,s e x ,
and risk factors. Stenosis of more than 50% were treated
with PTA 27 times (average, 3.4 per patient) in the virgin
treatment group. This study showed positive result with PTA
in the virgin graft, graft patency was signiﬁcantly increased
(P>0.0001), and the graft thrombosis signiﬁcantly
decreased (P = 0.0151) in the eight-patient virgin subset
when compared with the 24-patient nonvirgin subset of
the treatment group. There was a trend towards prolonged
graft patency (P = 0.0349) and a reduction of thromboses,
0.10 versus 0.44 thromboses per patient-dialysis year, in
the virgin-treatment group compared to the virgin-control6 International Journal of Nephrology
Table 2: Randomized trials with abnormal surveillance results and comparing intervention versus observation.
Name Total no.
of patients Intervention Conservative Surveillance methods used Primary outcome Result
Lumsden et al., 1997 [37] 64 32 32 Color ﬂow duplex scan Cumulative patency Negative
Martin et al., 1999 [64] 21 8 13 Color ﬂow duplex scan Virgin graft patency Positive
Dember et al., 2004 [63]6 4 3 2 3 2
Static venous
pressure/systolic blood
pressure ratio
Access survival Negative
Tessitore et al., 2004 [65] 79 43 36 Access ﬂow Access survival, thrombosis Positive
Scaﬀaro et al., 2009 [66] 108 53 58 Duplex scan Thrombosis Negative
group. This study has a major limitation due to very small
sample size.
In a more recent study by Dember et al. [63] in 2004,
64 high-risk patients with AVG with elevated static venous
pressure (≥0.4) detected by monthly measurement of static
venous pressure/systolic BP ratio (SVPR) were randomized
to observation and intervention groups. The intervention
group received angiography and repair of the identiﬁed
stenosis, whereas the observation group had stenosis repair
in the event of thrombosis or clinical evidence of access
dysfunction. The grafts enrolled in the study were both
virgin and nonvirgin grafts with a mean age of 321 days in
the intervention group and 350 in the observation group
and around one-third had previous intervention across both
groups. The follow-up period was 3.5 years. Although the
proportion of patients with a thrombotic event was greater
in the observation group (72%) than in the intervention
group (44%) (P = 0.04), time to access abandonment did
not diﬀer signiﬁcantly between the groups (hazard ratio
1.75, 95% CI 0.80–3.82, P = 0.16). One of the interesting
ﬁndings was that access loss from infection was higher in
the intervention group than in the observation group. This
was noted only in nonvirgin grafts. Most of the infections
occurred weeks or months after the procedure excluding
the idea of direct bacterial contamination but raises the
possibility that angioplasty may predispose to graft infection
in the setting of occult bacteremia.
The studies on AVF and AVG have diﬀerent study end
points, and the major limitation has been identifying a
hard end point for the interventions performed on dysfunc-
tional access. There has been growing perception that, with
increased emphasis on ﬁstula use, the prevalence of catheter
use is on the rise. In a study by Scaﬀaro [66], one of the
end points was increased need for central venous catheters
when an access fails. This does bring a new end point to
the interventions being introduced for dysfunctional access.
In this study, 108 patients were randomized to control and
intervention groups. The control group received clinical and
hemodynamic monitoring on a weekly basis; on detection of
dysfunction,patientwasreferredtoavascularsurgeon.Inthe
intervention arm, the patients received, along with clinical
andhemodynamic monitoring, aquarterlycolorﬂowduplex
ultrasound study for access ﬂow followed by angiography
when access ﬂow was under 500mL/min. 58 patients were
randomized to the control group and 53 to the intervention
group. The end points were the thrombosis of the ﬁstula
and need for central venous catheters. The outcomes were
evaluated at the end of 11 months. There was signiﬁcant
reduction in the need for central venous catheters (CVCs)
in the interventional group (25.9% versus 7.5% for control
and interventional group P = 0.021). Though there was no
signiﬁcantdiﬀerenceinthethrombosis(24.1%versus17.0%;
P = 0.487), the composite end point of AVF thrombosis or
CVC need was reduced by the interventional strategy (44.8%
versus 20.8%; P = 0.033). Considering that the ﬁstula
thrombosis rate is lower compared to the AVG, a followup of
11 months may have been shorter and the results may have
been diﬀerent with a longer followup. Since the cost of CVC
placement is seldom considered in cost analyses, this study
emphasizes the need for a global vascular access economic
analysis.
Theprospectivetrialsinvolvingarteriovenousﬁstulaeare
fewer compared to the AV grafts. Among the few which have
been performed, Tessitore et al. [39] conducted probably the
ﬁrst prospective controlled open trial in 2003 to evaluate
the eﬀect of prophylactic PTA of stenosis with no known
accessdysfunctiononsurvivalofnativevirginforearmradio-
cephalic AVF. Sixty-two functioning ﬁstulas with stenosis
were randomized to intervention versus controlled groups
(32 versus 30, resp.). The end points were either ﬁstula
thrombosis or surgical revision due to dysfunction, but it
is not clear if repeat angioplasty for access dysfunction was
an end point or if not how many of the accesses had repeat
angioplasty. The result showed fourfold increase in median
survival and a 2.87-fold decrease in risk of failure. PTA was
also associated with a signiﬁcant decrease risk of hospital-
ization, central venous catheterization, and thrombectomy.
Subsequently the same group conducted a 5-year random-
ized controlled trial [65]o n7 9m a t u r ef o r e a r mA V Ft o
evaluate the eﬀect of blood ﬂow surveillance and preemptive
repair of stenosis on ﬁstula longevity. Surveillance program
included ultrasound dilution measurement of access ﬂow on
a quarterly basis, ability to maintain the prescribed blood
ﬂow rate, and urea-based access recirculation. Forty-three
patients were allocated to preemptive angioplasty and 36 to
the control group. Primary patency rate was improved in
the intervention group (RR 3.35 with 95% CI 1.44–7.78,
P = 0.003) and a trend towards improved secondary patency
rate (RR 2.66 with 95% CI 0.98–6.85, P = 0.055). The study
analysis also identiﬁed that higher baseline access ﬂow (Qa)International Journal of Nephrology 7
aswellashigherpostinterventionQaaremajordeterminants
of longer failure free interval and AVF useful life. The results
suggest that the quality of the intervention is a major factor
in improving patency duration.
All the studies conducted so far have small sample
size, much lower than what is required to see a signiﬁcant
diﬀerence, and the quality of the studies reported was
moderate to poor. In 2008 Tonelli et al. [69]c o n d u c t e da
meta-analysisofthe 12 RCTs, 8involving AVGand fourtrials
on AVF. In ﬁstula trials, access blood ﬂow or ultrasound-
basedscreeningsigniﬁcantlydecreasedtheaccessthrombosis
(RR 0.47, 95% CI 0.28–0.77; 360 participants; I2 = 8%)
but not the risk of ﬁstula loss (RR 0.65; 95% CI 0.28–1.51;
I2 = 0 % )o rr e s o u r c eu s e .I nc a s eo fg r a f t st h e r ew a sn o
decrease in risk of thrombosis (RR 0.94; 95% CI 0.77–1.16;
446 participants; I2 = 0%) or access loss (RR 1.08; 95%
0.83–1.40; I2 = 0%). In the same year, another meta-analysis
conducted by Casey et al. [70] echoed similar results.
4. Conclusions
A lasting and properly functioning access is crucial to
provide adequate dialysis to improve the quality of life of
maintenance hemodialysis patients and to reduce the huge
access-related cost in this population. We are still in dilemma
as to the conﬂicting results of observational studies and
randomized control trials (RCTs) on access surveillance. It
shouldbenotedthat,inallofthestudiesdescribedabove,the
samplesizeusedwassmallandmuchsmallerthanthatwhich
would have been derived using a Pearson’s events-driven
model which increases the sample size 4–6-fold. Sample
size of around 500 is needed even for the most simplistic
RCT design to see a meaningful diﬀerence with adequate
power. All available RCTs have sample size less than 200
subjects, and some were as small as 30–50 allocated to one
of 2-3 groups. This could be a major reason for failure to
show any beneﬁcial eﬀect. Another major limitation could
be the lack of standardized tools to assess the success of the
intervention of the stenotic lesions in most of the studies.
Anatomical success does not translate to improvement of the
functional/physiological parameters due to elastic recoil and
other factors.
T h eb i g g e rq u e s t i o ni sw h a tw ea r et r y i n gt oa c h i e v eb y
performing a surveillance program? What are the hard end
points? Is angioplasty the right treatment of a dysfunctional
ﬁstula? Should we consider prevention of thrombosis with-
out improved longevity a worthy outcome? In spite of all
the recent advances and increased procedures, why has the
evidence for increased life of a vascular access been eluding
us? All these questions lead us to the need of the hour, that
is, larger multicenter scientiﬁcally sound controlled studies
with adequate sample size.
References
[1] K. Konner, “A primer on the av ﬁstula—achilles’ heel,
but also Cinderella of haemodialysis,” Nephrology Dialysis
Transplantation, vol. 14, no. 9, pp. 2094–2098, 1999.
[2] Fistula First Breakthrough Initiative: June 2011.
[3] P. Eggers, “Trends in medicare expenditure for vascular
access,” Tech. Rep., Cincinnati Hemodialysis VascularAccess
Symposium, Cincinnati, Ohio, USA, 2004.
[4] A. Besarab, A. Asif, P. Roy-Chaudhury, L. M. Spergel, and P.
Ravani, “The native arteriovenous ﬁstula in 2007 surveillance
andmonitoring,”JournalofNephrology,vol.20,no.6,pp.656–
667, 2007.
[5] “NKF-K/DOQI clinical practiceguidelines for vascular access:
update 2006,” American Journal of Kidney Diseases, vol. 48,
supplement 1, pp. S176–S276, 2006.
[6] Medicare and Medicaid Programs, Conditions for Coverage
for End-Stage Renal Disease Facilities; Final Rule: Rules and
Regulations,PartII,vol.73,DepartmentofHealthandHuman
Services, Federal Register, 2008.
[7] G. Beathard, “Physical examination: the forgotten tool,” in
Dialysis Access: A Multidisciplinary Approach,J .R .G r a ya n d
J. J. Sands, Eds., pp. 111–118, Lippincott Williams & Wilkins,
Philadelphia, Pa, USA, 2002.
[8] M. B. Thomsen and G. Stenport, “Evaluation of clinical exam-
ination preceding surgical treatment of AV-ﬁstula problems.
Is angiography necessary?” Acta Chirurgica Scandinavica, vol.
151, no. 2, pp. 133–137, 1985.
[9] A. Asif, C. Leon, L. C. Orozco-Vargas et al., “Accuracy
of physical examination in the detection of arteriovenous
ﬁstula stenosis,” Clinical Journal of the American Society of
Nephrology, vol. 2, no. 6, pp. 1191–1194, 2007.
[ 1 0 ] R .P .C a m p o s ,D .C .C h u l a ,S .P e r r e t o ,M .C .R i e l l a ,a n dM .M .
Do Nascimento, “Accuracy of physical examination and intra-
access pressure in the detection of stenosis in hemodialysis
arteriovenous ﬁstula,” Seminars in Dialysis,v o l .2 1 ,n o .3 ,p p .
269–273, 2008.
[11] J. H. M. Smits, J. van der Linden, E. C. Hagen et al.,
“Graft surveillance: venous pressure, access ﬂow, or the
combination?” Kidney International, vol. 59, no. 4, pp. 1551–
1558, 2001.
[12] G. A. Beathard, “The treatment of vascular access graft
dysfunction: a nephrologist’s view and experience,” Advances
in Renal ReplacementTherapy, vol. 1, no. 2, pp. 131–147, 1994.
[13] A. Besarab, “Advances in end-stage renal diseases 2000. Access
monitoring methods,” Blood Puriﬁcation,v o l .1 8 ,n o .4 ,p p .
255–259, 2000.
[14] J. K. Leypoldt, “Diagnostic methods for vascular access: access
ﬂowmeasurements,”ContributionstoNephrology,vol.137,pp.
31–37, 2002.
[15] F. Lopot, B. Nejedly, S. Sulkova, and J. Blaha, “Comparison
of diﬀerent techniques of hemodialysis vascular access ﬂow
evaluation,” International Journal of Artiﬁcial Organs, vol. 26,
no. 12, pp. 1056–1063, 2003.
[16] G. Bacchini, A. Cappello, V. La Milia, S. Andrulli, and
F. Locatelli, “Color Doppler ultrasonography imaging to
guide transluminal angioplasty of venous stenosis,” Kidney
International, vol. 58, no. 4, pp. 1810–1813, 2000.
[17] M. F. Gadallah, W. D. Paulson, B. Vickers, and J. Work,
“Accuracy of Doppler ultrasound in diagnosing anatomic
stenosis of hemodialysis arteriovenous access as compared
with ﬁstulography,” American Journal of Kidney Diseases, vol.
32, no. 2, pp. 273–277, 1998.
[18] J. Malik, M. Slavikova, H. Malikova, and J. Maskova, “Many
clinicallysilentaccessstenosescanbeidentiﬁedbyultrasonog-
raphy,”JournalofNephrology,vol.15,no.6,pp.661–665,2002.
[ 1 9 ]G .Z a s u w a ,S .F r i n a k ,A .B e s a r a b ,E .P e t e r s o n ,a n dJ .Y e e ,
“Automated intravascular access pressure surveillance reduces
thrombosis rates,” Seminars in Dialysis, vol. 23, no. 5, pp. 527–
535, 2010.8 International Journal of Nephrology
[20] S. Frinak, G. Zasuwa, T. Dunfee, A. Besarab, and J. Yee,
“Dynamic venous access pressure ratio test for hemodialysis
access monitoring,” American Journal of Kidney Diseases, vol.
40, no. 4, pp. 760–768, 2002.
[21] N. Krivitski and S. Gantela, “Access blood ﬂow: debate
continues,” Seminars in Dialysis, vol. 14, no. 6, pp. 460–461,
2001.
[22] A. Besarab, K. L. Sullivan, R. Ross, and M. J. Moritz, “The
utility of intra-access pressure monitoring in detecting and
correcting venous outlet stenoses prior to thrombosis,” Kidney
International, vol. 47, no. 5, pp. 1364–1373, 1995.
[23] K. L. Sullivan and A. Besarab, “Hemodynamic screening and
early percutaneous intervention reduce hemodialysis access
thrombosis and increase graft longevity,” Journal of Vascular
and Interventional Radiology, vol. 8, no. 2, pp. 163–170, 1997.
[24] A. Besarab, S. Frinak, R. A. Sherman et al., “Simpliﬁed
measurement of intra-access pressure: besarab et. al.,” Journal
of the American Society of Nephrology, vol. 9, no. 2, pp. 284–
289, 1998.
[25] S. Frinak, G. Zasuwa, T. Dunfee et al., “Computerized
measurement of intra-access pressure,” American Journal of
Kidney Diseases, vol. 40, pp. 760–768, 2002.
[26] A. Asif, F. N. Gadalean, D. Merrill et al., “Inﬂow stenosis in
arteriovenous ﬁstulas and grafts: a multicenter, prospective
study,” Kidney International, vol. 67, no. 5, pp. 1986–1992,
2005.
[ 2 7 ]R .B o z o f ,M .K a t s ,J .B a r k e r ,a n dM .A l l o n ,“ T i m et o
symptomaticvascularstenosisatdiﬀerentlocationsinpatients
with arteriovenous grafts,” Seminars in Dialysis, vol. 21, no. 3,
pp. 285–288, 2008.
[28] A. Besarab, R. Ross, F. Ai-Adel et al., “The relation of intra
access pressure to ﬂoe,” Journal of the American Society of
Nephrology, vol. 7, p. 483, 1995.
[29] A. Besarab, T. Lubkowski, A. Vu, A. Aslam, and S. Frinak,
“Eﬀects of systemic hemodynamics on ﬂow within vascular
accesses used for hemodialysis,” ASAIO Journal, vol. 47, no.
5, pp. 501–506, 2001.
[30] R. Dikow, V. Schwenger, M. Zeier, and E. Ritz, “Do AV ﬁstulas
contribute to cardiac mortality in hemodialysis patients?”
Seminars in Dialysis, vol. 15, no. 1, pp. 14–17, 2002.
[31] J. J. White, S. J. Ram, S. A. Jones, S. J. Schwab, and W. D.
Paulson, “Inﬂuence of luminal diameters on ﬂow surveillance
of hemodialysis grafts: insights from a mathematical model,”
Clinical journal of the American Society of Nephrology, vol. 1,
no. 5, pp. 972–978, 2006.
[32] J. J. White, S. A. Jones, S. J. Ram, S. J. Schwab, and W.
D. Paulson, “Mathematical model demonstrates inﬂuence of
luminal diameters on venous pressure surveillance,” Clinical
Journal of the American Society of Nephrology,v o l .2 ,n o .4 ,p p .
681–687, 2007.
[33] S. J. Schwab, M. J. Oliver, P. Suhocki, and R. McCann,
“Hemodialysis arteriovenous access: detection of stenosis and
response to treatment by vascular access blood ﬂow,” Kidney
International, vol. 59, no. 1, pp. 358–362, 2001.
[ 3 4 ]N .T e s s i t o r e ,V .B e d o g n a ,E .M e l i l l ie ta l . ,“ I ns e a r c ho f
an optimal bedside screening program for arteriovenous
ﬁstula stenosis,” Clinical Journal of the American Society of
Nephrology, vol. 6, no. 4, pp. 819–826, 2011.
[35] L. E. M. Duijm, Y. S. Liem, R. H. H. van der Rijt et al.,
“Inﬂow stenoses in dysfunctional hemodialysis access ﬁstulae
and grafts,” American Journal of Kidney Diseases,v o l .4 8 ,n o .1 ,
pp. 98–105, 2006.
[36] A. Besarab, T. Lubkowski, S. Frinak, S. Ramanathan, and F.
Escobar, “Detection of access strictures and outlet stenoses in
vascular accesses: which test is best?” ASAIO Journal, vol. 43,
no. 5, pp. M543–M547, 1997.
[37] A.B.Lumsden,M.J.MacDonald, andD. Kikeri,“Prophylactic
balloon angioplasty fails to prolong the patency of expanded
polytetraﬂuoroethylene arteriovenous grafts: results of a
prospective randomized study,” Journal of Vascular Surgery,
vol. 26, no. 3, Article ID 10.1016/S0741-5214(97)70031-4, pp.
382–392, 1997.
[38] M. Allon and M. L. Robbin, “Hemodialysis vascular access
monitoring: Current concepts,” Hemodialysis International,
vol. 13, no. 2, pp. 153–162, 2009.
[39] N. Tessitore, G. Mansueto, V. Bedogna et al., “A prospective
controlled trial on eﬀect of percutaneous transluminal angio-
plasty on functioning arteriovenous ﬁstulae survival,” Journal
of the American Society of Nephrology, vol. 14, no. 6, pp. 1623–
1627, 2003.
[40] B. M. Murray, A. Herman, B. Mepani et al., “Access ﬂow after
angioplasty predicts subsequent arteriovenour graft survival,”
Journal of Vascular and Interventional Radiology, vol. 17, no. 2,
pp. 303–308, 2006.
[41] J. van der Linden, J. H. Smits, J. H. Assink et al., “Short-
andlong-termfunctionaleﬀectsofpercutaneoustransluminal
angioplasty in hemodialysis vascular access,” Journal of the
American Society of Nephrology, vol. 13, no. 3, pp. 715–720,
2002.
[42] R. E. May, J. Himmelfarb, M. Yenicesu et al., “Predictive
measures of vascular access thrombosis,” Kidney International,
vol. 52, no. 6, pp. 1656–1662, 1997.
[43] E. Wang, D. Schneditz, C. Nepomuceno et al., “Predictive
value of access blood ﬂow in detecting access thrombosis,”
ASAIO Journal, vol. 44, no. 5, pp. M555–M558, 1998.
[44] W. D. Paulson, S. J. Ram, C. G. Birk, and J. Work, “Does blood
ﬂow accurately predict thrombosis or failure of hemodialysis
synthetic grafts? a meta-analysis,” American Journal of Kidney
Diseases, vol. 43, no. 3, pp. 478–485, 1999.
[45] G. McDougal and R. Agarwal, “Clinical performance char-
acteristics of hemodialysis graft monitoring,” Kidney Interna-
tional, vol. 60, no. 2, pp. 762–766, 2001.
[46] N. R. Neyra, T. A. Ikizler, R. E. May et al., “Change in access
blood ﬂow over time predicts vascular access thrombosis,”
Kidney International, vol. 54, no. 5, pp. 1714–1719, 1998.
[47] K. R. Polkinghorne, R. C. Atkins, and P. G. Kerr, “Native arte-
riovenous ﬁstula blood ﬂow and resistance during hemodial-
ysis,” American Journal of Kidney Diseases,v o l .4 1 ,n o .1 ,p p .
132–139, 2003.
[48] R. M. Huisman, M. van Dijk, C. de Bruin et al., “Within-
sessionandbetween-sessionvariabilityofhaemodialysisshunt
ﬂow measurements,” Nephrology Dialysis Transplantation, vol.
20, no. 12, pp. 2842–2847, 2005.
[49] J.J.Sands,P.A.Jabyac,C.L.Miranda,andB.J.Kapsick,“Inter-
vention based on monthly monitoring decreases hemodialysis
access thrombosis,” ASAIOJournal,vol.45,no.3,pp.147–150,
1999.
[50] P. Mccarley, R. L. Wingard, Y. Shyr, W. Pettus, R. M. Hakim,
and T. Ikizler, “Vascular access blood ﬂow monitoring reduces
access morbidity and costs,” Kidney International, vol. 60, no.
3, pp. 1164–1172, 2001.
[ 5 1 ]H .H o e b e n ,A .K .A b u - A l f a ,R .F .R e i l l y ,J .E .A r u n y ,K .
Bouman, and M. A. Perazella, “Vascular access surveillance:
evaluation of combining dynamic venous pressure and vas-
cular access blood ﬂow measurements,” American Journal of
Nephrology, vol. 23, no. 6, pp. 403–408, 2003.
[52] S. Glazer, J. Diesto, P. Crooks et al., “Going beyond the
kidneydiseaseoutcomesqualityinitiative:hemodialysisaccessInternational Journal of Nephrology 9
experience at Kaiser permanente Southern California,” Annals
of Vascular Surgery, vol. 20, no. 1, pp. 75–82, 2006.
[53] L. C. Plantinga, B. G. Jaar, B. Astor et al., “Association of clinic
vascular access monitoring practices with clinical outcomes in
hemodialysis patients,” Nephron—Clinical Practice, vol. 104,
no. 4, pp. c151–c159, 2006.
[54] H. Shahin, G. Reddy, M. Sharafuddin, D. Katz, B. S. Franzwa,
and B. S. Dixon, “Monthly access ﬂow monitoring with
increased prophylactic angioplasty did not improve ﬁstula
patency,” Kidney International, vol. 68, no. 5, pp. 2352–2361,
2005.
[55] G. Zasuwa, S. Frinak, A. Besarab, E. Peterson, and J. Yee,
“Automated intravascular access pressure surveillance reduces
thrombosis rates,” Seminars in Dialysis, vol. 23, no. 5, pp. 527–
535, 2010.
[56] J. Malik, M. Slavikova, J. Svobodova, and V. Tuka, “Regular
ultrasonographic screening signiﬁcantly prolongs patency of
PTFE grafts,” Kidney International, vol. 67, no. 4, pp. 1554–
1558, 2005.
[57] D. A. Mayer, R. G. Zingale, and M. J. Tsapogas, “Duplex
scanning of expanded polytetraﬂuoroethylene dialysis shunts:
impact on patient management and graft survival,” Vascular
Surgery, vol. 27, no. 9, pp. 647–658, 1993.
[58] L. M. Moist, D. N. Churchill, A. A. House et al., “Regular
monitoring of access ﬂow compared with monitoring of
venous pressure fails to improve graft survival,” Journal of the
AmericanSocietyof Nephrology, vol. 14, no. 10, pp. 2645–2653,
2003.
[59] K. R. Polkinghorne, K. K. Lau, A. Saunder, R. C. Atkins, and
P. G. Kerr, “Does monthly native arteriovenous ﬁstula blood-
ﬂow surveillance detect signiﬁcant stenosis—a randomized
controlled trial,” Nephrology Dialysis Transplantation, vol. 21,
no. 9, pp. 2498–2506, 2006.
[ 6 0 ]M .L .R o b b i n ,R .F .O s e r ,J .Y .L e e ,G .R .H e u d e b e r t ,S .
T. Mennemeyer, and M. Allon, “Randomized comparison of
ultrasound surveillance and clinical monitoring on arteriove-
nous graft outcomes,” Kidney International,v o l .6 9 ,n o .4 ,p p .
730–735, 2006.
[61] R. Roca-Tey, R. Samon Guasch, O. Ibrik et al., “Vascular access
surveillance with blood ﬂow monitoring: a prospective study
with 65 patients,” Nefrologia, vol. 24, no. 3, pp. 246–252, 2004.
[62] S. J. Ram, J. Work, G. C. Caldito, J. M. Eason, A. Pervez,
and W. D. Paulson, “A randomized controlled trial of blood
ﬂow and stenosis surveillance of hemodialysis grafts,” Kidney
International, vol. 64, no. 1, pp. 272–280, 2003.
[63] L. M. Dember, E. F. Holmberg, and J. S. Kaufman, “Ran-
domizedcontrolledtrialofprophylacticrepairofhemodialysis
arteriovenous graft stenosis,” Kidney International, vol. 66, no.
1, pp. 390–398, 2004.
[64] L.G.Martin,M.J.MacDonald, D.Kikeri,G.A.Cotsonis,L.A.
Harker, and A. B. Lumsden, “Prophylactic angioplasty reduces
thrombosis in virgin ePTFEarteriovenous dialysis grafts with
greater than 50% stenosis: subset analysis of a prospectively
randomized study,” Journal of Vascular and Interventional
Radiology, vol. 10, no. 4, pp. 389–396, 1999.
[65] N. Tessitore, G. Lipari, A. Poli et al., “Can blood ﬂow
surveillance and pre-emptive repair of subclinical stenosis
prolong theusefullifeofarteriovenous ﬁstulae? Arandomized
controlled study,” Nephrology Dialysis Transplantation, vol. 19,
no. 9, pp. 2325–2333, 2004.
[66] L. A. Scaﬀaro, J. A. Bettio, S. A. Cavazzola et al., “Maintenance
of hemodialysis arteriovenous ﬁstulas by an interventional
strategy: clinical and duplex ultrasonographic surveillance
followed by transluminal angioplasty,” Journal of Ultrasound
in Medicine, vol. 28, no. 9, pp. 1159–1165, 2009.
[67] C. L. Miranda and J. J. Sands, “Flow volumes as a predictor
of hemodialysis access failure,” Journal of Vascular Technology,
vol. 22, no. 2, pp. 73–76, 1998.
[68] L.G.Martin,M.J.MacDonald,D.Kikeri,G.A.Cotsonis,L.A.
Harker, and A. B. Lumsden, “Prophylactic angioplasty reduces
thrombosis in virgin ePTFE arteriovenous dialysis grafts with
greater than 50% stenosis: subset analysis of a prospectively
randomized study,” Journal of Vascular and Interventional
Radiology, vol. 10, no. 4, pp. 389–396, 1999.
[69] M. Tonelli, M. James, N. Wiebe, K. Jindal, and B. Hem-
melgarn, “Ultrasound monitoring to detect access stenosis
inhemodialysis patients,” American Journal of Kidney Diseases,
vol. 51, no. 4, pp. 630–640, 2008.
[70] E. T. Casey, M. H. Murad, A. Z. Rizvi et al., “Surveillance
of arteriovenous hemodialysis access: a systematic review
and meta-analysis,” Journal of Vascular Surgery, vol. 48,
supplement 5, pp. S48–S54, 2008.